Hepatocyte growth factor in dampening liver immune-mediated pathology in acute viral hepatitis without compromising antiviral activity

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 4, 2014, Pages 878-886

  Aguilar Valenzuela, Renan ^a   Carlsen, Eric D ^a   Liang, Yuejin ^a   Soong, Lynn ^a   Sun, Jiaren ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Dendritic cells; Hepatocyte growth factor; T cell inhibition; Viral hepatitis

Indexed keywords

ACUTE PHASE PROTEIN; ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; CD40 ANTIGEN; CXCL9 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EXPERIMENTAL LIVER INJURY; GENE DELIVERY SYSTEM; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRAL CLEARANCE; VIRUS HEPATITIS;

DENDRITIC CELLS; HEPATOCYTE GROWTH FACTOR; T CELL INHIBITION; VIRAL HEPATITIS;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD40; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHEMOKINE CXCL9; DENDRITIC CELLS; GENE EXPRESSION; HEPATITIS, VIRAL, ANIMAL; HEPATOCYTE GROWTH FACTOR; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-6; LIVER; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896350971     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12456     Document Type: Article

References (50)

1. Botterel F, Farrugia C, Ichai P, Costa JM, Saliba F, Bretagne S. Real-time PCR on the first galactomannan-positive serum sample for diagnosing invasive aspergillosis in liver transplant recipients. Transpl. Infect. Dis. 2008; 10: 333-338.
2. Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008; 14 (Suppl. 2): S67-79.
3. Barnes E, Folgori A, Capone S etal. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 2012; 4: 115ra1.
4. Raper SE, Chirmule N, Lee FS etal. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003; 80: 148-158.
5. Ajuebor MN, Chen Q, Strieter RM, Adegboyega PA, Aw TY. V(alpha)14iNKT cells promote liver pathology during adenovirus infection by inducing CCL5 production: implications for gene therapy. J. Virol. 2010; 84: 8520-8529.
6. + regulatory T cells. Proc. Natl Acad. Sci. U.S.A. 2010; 107: 6424-6429.
7. Burcelin R, Garidou L, Pomie C. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases. Semin. Immunol. 2012; 24: 67-74.
8. Makino H, Aoki M, Hashiya N etal. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler. Thromb. Vasc. Biol. 2012; 32: 2503-2509.
9. Morimoto K, Amano H, Sonoda F etal. Alveolar macrophages that phagocytose apoptotic neutrophils produce hepatocyte growth factor during bacterial pneumonia in mice. Am. J. Respir. Cell Mol. Biol. 2001; 24: 608-615.
10. Grenier A, Chollet-Martin S, Crestani B etal. Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils. Blood 2002; 99: 2997-3004.
11. Giannopoulou M, Dai C, Tan X, Wen X, Michalopoulos GK, Liu Y. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. Am. J. Pathol. 2008; 173: 30-41.
12. Ueki T, Kaneda Y, Tsutsui H etal. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 1999; 5: 226-230.
13. Baek JH, Birchmeier C, Zenke M, Hieronymus T. The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J. Immunol. 2012; 189: 1699-1707.
14. Imado T, Iwasaki T, Kataoka Y etal. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation. Blood 2004; 104: 1542-1549.
15. Kosai K, Matsumoto K, Funakoshi H, Nakamura T. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 1999; 30: 151-159.
16. Okunishi K, Dohi M, Fujio K etal. Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice. J. Immunol. 2007; 179: 5504-5513.
17. Giebeler A, Boekschoten MV, Klein C etal. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology 2009; 137: 297-308; e1-4.
18. Okunishi K, Dohi M, Nakagome K etal. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J. Immunol. 2005; 175: 4745-4753.
19. Yang J, Chen S, Huang L, Michalopoulos GK, Liu Y. Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth. Hepatology 2001; 33: 848-859.
20. Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS ONE 2010; 5: e15384.
21. Gordin M, Tesio M, Cohen S etal. c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J. Immunol. 2010; 185: 2020-2031.
22. Xia JL, Dai C, Michalopoulos GK, Liu Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol. 2006; 168: 1500-1512.
23. Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, Nakamura T. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice. Kidney Int. 2000; 57: 937-948.
24. Okayama K, Azuma J, Dosaka N etal. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 2012; 59: 958-965.
25. Lee JJ, Liu D, Lee JS etal. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J. Natl Cancer Inst. 2001; 93: 1081-1088.
26. Schmitz V, Dombrowski F, Prieto J etal. Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. Hepatology 2006; 44: 430-439.
27. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
28. Maier H, Isogawa M, Freeman GJ, Chisari FV. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J. Immunol. 2007; 178: 2714-2720.
29. Lang KS, Georgiev P, Recher M etal. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 2006; 116: 2456-2463.
30. Rosenblum JM, Shimoda N, Schenk AD etal. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J. Immunol. 2010; 184: 3450-3460.
31. Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007; 15: 143-146.
32. Kerdiles YM, Beisner DR, Tinoco R etal. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 2009; 10: 176-184.
33. Bu X, Zhou Y, Zhang H etal. Systemic administration of naked plasmid encoding HGF attenuates puromycin aminonucleoside-induced damage of murine glomerular podocytes. Am. J. Physiol. Renal Physiol. 2011; 301: F784-792.
34. Oketani M, Ido A, Nakayama N etal. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol. Res. 2013; 43: 97-105.
35. Marin-Serrano E, Jaquotot-Herranz M, Casanova-Martinez L, Tur-Gonzalez R, Segura-Cabral JM. Ectopic sebaceous glands in the esophagus. Rev. Esp. Enferm. Dig. 2010; 102: 141-142.
36. Funakoshi H, Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin. Chim. Acta 2003; 327: 1-23.
37. Yan J, Jie Z, Hou L etal. Parenchymal expression of CD40 exacerbates adenovirus-induced hepatitis in mice. Hepatology 2011; 53: 1455-1467.
38. Adams DH, Harvath L, Bottaro DP etal. Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 7144-7148.
39. Ohnishi H, Oka K, Mizuno S, Nakamura T. Identification of mannose receptor as receptor for hepatocyte growth factor beta-chain: novel ligand-receptor pathway for enhancing macrophage phagocytosis. J. Biol. Chem. 2012; 287: 13371-13381.
40. Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J. Am. Soc. Nephrol. 2004; 15: 2637-2647.
41. Gong R, Rifai A, Ge Y, Chen S, Dworkin LD. Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J. Biol. Chem. 2008; 283: 7401-7410.
42. + T cell deletion and viral persistence in vivo. Immunity 2009; 31: 145-157.
43. Boettler T, Cheng Y, Ehrhardt K, von Herrath M. TGF-beta blockade does not improve control of an established persistent viral infection. Viral Immunol. 2012; 25: 232-238.
44. Garidou L, Heydari S, Gossa S, McGavern DB. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection. J. Virol. 2012; 86: 7060-7071.
45. Jin HT, Anderson AC, Tan WG etal. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 14733-14738.
46. + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 2010; 120: 4546-4557.
47. Sabatos CA, Chakravarti S, Cha E etal. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 2003; 4: 1102-1110.
48. Sanchez-Fueyo A, Tian J, Picarella D etal. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 2003; 4: 1093-1101.
49. Teijaro JR, Ng C, Lee AM etal. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013; 340: 207-211.
50. Wilson EB, Yamada DH, Elsaesser H etal. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013; 340: 202-207.